Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease

NCT06079190 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06079190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06079190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
October 20, 2023
Completion date
August 18, 2026
Enrollment
367 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease